NAC (N-Acetyl Cysteine): The Supplement the FDA Tried to Ban — and Why It’s Worth Understanding

N-acetyl cysteine has had one of the stranger regulatory histories of any supplement on the market. It’s been used in emergency medicine for decades, studied in over 1,000 clinical trials, and is on the World Health Organization’s list of essential medicines. Then in 2021, the FDA argued it couldn’t be sold as a dietary supplement at all.

The story of NAC tells you something important about how supplement regulation works — and about why this particular compound keeps showing up across such a wide range of health applications, from liver protection to lung function to longevity research.

This article covers what NAC actually does, what the evidence supports, where the limitations are, and how to think about dosing if you’re considering it.

What Is NAC?

NAC is the acetylated form of the amino acid L-cysteine. The acetyl group makes it more stable and better absorbed than plain cysteine. Once inside the body, NAC is converted to cysteine, which is then used to synthesize glutathione — the body’s primary endogenous antioxidant.

Glutathione is a tripeptide (glutamate + cysteine + glycine), and cysteine is the rate-limiting substrate. This means NAC supplementation directly increases cellular glutathione levels. That single mechanism explains most of NAC’s documented benefits.

Beyond glutathione synthesis, NAC has direct antioxidant activity of its own (the free thiol group scavenges reactive oxygen species), and it has mucolytic properties — it breaks disulfide bonds in mucus proteins, reducing viscosity. This last property is what put it on hospital formularies.

The FDA Controversy: What Actually Happened

In 2021, the FDA issued warning letters to several supplement companies selling NAC products, arguing that NAC couldn’t legally be sold as a dietary supplement because it was “first approved as a new drug” in 1963 (as the mucolytic medication Mucomyst). Under the Dietary Supplement Health and Education Act, a compound that was first studied as a drug before being introduced as a supplement occupies a regulatory gray zone.

The supplement industry pushed back hard. The Council for Responsible Nutrition and others argued that NAC had a long history of use as a supplement independent of its drug applications, and that the FDA’s position was both legally uncertain and scientifically arbitrary.

In 2022, the FDA issued updated guidance essentially saying it would defer enforcement while it reviewed the issue. As of 2024, NAC remains widely available as a supplement, but the regulatory situation remains unresolved.

This matters practically for two reasons: (1) the regulatory uncertainty is real, and (2) the controversy revealed that the FDA does not always draw these lines based on evidence of harm — NAC is one of the better-studied compounds in this space.

What the Research Actually Supports

Liver Protection (High-Quality Evidence)

The most robust human evidence for NAC involves liver protection. Intravenous NAC is the standard of care for acetaminophen (paracetamol) overdose — it restores glutathione depleted by acetaminophen’s toxic metabolite NAPQI, preventing acute liver failure. This is well-established medicine, not a supplement claim.

For non-emergency contexts, the evidence is more nuanced but still meaningful:

• Non-alcoholic fatty liver disease (NAFLD): A 2012 RCT by Khoshbaten et al. (published in Hepatitis Monthly) found that 600 mg/day NAC over 12 months significantly reduced liver enzyme levels (ALT, AST) compared to placebo in NAFLD patients.
• Alcohol-related liver stress: Several studies have found NAC supplementation reduces markers of oxidative stress and liver injury in alcohol-exposed individuals, consistent with its glutathione-restoring mechanism.

Psychiatric Applications (Growing but Contested Evidence)

The psychiatric literature on NAC has grown substantially since Berk et al.’s 2008 RCT showing benefit in bipolar depression. The proposed mechanism: glutathione depletion and oxidative stress are increasingly implicated in several psychiatric conditions, and NAC appears to modulate both glutamate signaling and inflammatory pathways relevant to mood.

Key studies:

• Bipolar depression: Berk et al. (2008, Biological Psychiatry) — 2,000 mg/day NAC over 24 weeks produced significant improvement in depression scores vs placebo in 75 patients. Effect size was moderate (Cohen’s d ≈ 0.5), and benefits emerged slowly, peaking around week 20.
• OCD: A 2016 meta-analysis by Ghanizadeh et al. found NAC augmentation improved OCD symptom scores as an add-on to SSRIs.
• Addiction/craving: Several RCTs have examined NAC in substance use disorders, with the most consistent findings in cannabis dependence (Gray et al., 2012) and cocaine craving. The effect size is modest but notable given the mechanistic plausibility.

Important caveat: Most psychiatric NAC trials are small, and effect sizes are modest. This is not a replacement for established treatments — it’s a potential adjunct with a reasonably good safety profile.

Lung Function and Respiratory Health

The mucolytic mechanism is well-established. NAC reduces mucus viscosity by breaking disulfide bonds in mucoproteins. In clinical settings, this applies to:

• Chronic obstructive pulmonary disease (COPD): A 2014 meta-analysis in Thorax (Tse et al.) analyzed 13 RCTs totaling 4,155 patients and found that high-dose NAC (1,200 mg/day) significantly reduced COPD exacerbations (OR 0.75, 95% CI 0.62–0.91). The 600 mg/day dose used in most older studies did not reach statistical significance.
• Chronic bronchitis: The mucolytic effect reduces cough frequency and mucus production in clinical trials.

Longevity and Aging Research (Preclinical — Early Stage)

The most speculative applications involve NAC’s role in longevity pathways. Glutathione depletion is a consistent feature of aging — older adults typically have lower intracellular glutathione than younger people — and restoring it has theoretical anti-aging appeal.

Several animal studies show life extension with NAC supplementation, and mechanistic work has identified interactions with mTOR, Nrf2 activation (via cysteine’s effect on Keap1), and mitochondrial function. However, robust human longevity data does not yet exist.

The NIA’s Interventions Testing Program has evaluated NAC in mice with mixed results. It remains speculative as a longevity intervention in humans.

What NAC Probably Does Not Do

• Protect against COVID-19 or respiratory infections as a primary defense: Several researchers proposed this during 2020–2021 based on mechanistic arguments, but clinical trial results were inconsistent.
• Significantly enhance athletic performance: A few studies have shown modest reductions in oxidative stress markers with NAC during high-intensity exercise, but effect sizes on performance outcomes are small and inconsistent.
• Provide meaningful cognitive enhancement: Despite the mechanistic logic (oxidative stress is elevated in cognitive decline), clinical evidence for cognition in healthy adults is weak.

How NAC Compares to Direct Glutathione Supplementation

One obvious question: why not just take glutathione directly?

The problem is absorption. Oral glutathione is largely degraded in the GI tract before it can be absorbed intact. A 2014 study by Richie et al. found that oral glutathione supplementation at 500 mg/day over 6 months did modestly raise whole-blood glutathione, but absorption rates are unreliable and variable.

NAC, by contrast, is absorbed as cysteine and drives intracellular glutathione synthesis directly. It’s a more reliable strategy for raising cellular glutathione than supplementing glutathione itself.

Liposomal glutathione formulations improve absorption somewhat, but remain more expensive and less well-studied than NAC.

Dosing Protocol

Doses vary significantly by application:

Practical notes:

• The 600 mg dose is the most commonly sold and studied for general health applications. For COPD and psychiatric applications, the evidence points to higher doses (1,200–2,000 mg).
• Take with food to reduce GI side effects (nausea is the most common complaint at higher doses).
• Consider taking NAC with glycine — the other rate-limiting substrate in glutathione synthesis. The NAC + glycine combination (1,000 mg each) has been studied as a more complete glutathione precursor strategy (Kumar et al., 2021, Journal of Gerontology).
• If taking for psychiatric applications, be aware that benefits may not manifest for 8–20 weeks. Don’t discontinue early.

NAC + Glycine: The Underrated Combination

One of the more interesting developments in the NAC literature is the emerging evidence for NAC combined with glycine (GlyNAC). Glutathione synthesis requires three amino acids — glutamate (not typically limiting), cysteine (limiting, supplied by NAC), and glycine (also limiting in older adults).

A 2021 pilot RCT by Kumar et al. at Baylor College of Medicine found that 24 weeks of GlyNAC supplementation in older adults: - Increased red blood cell glutathione by ~230% - Reduced oxidative stress markers - Improved mitochondrial function markers - Improved muscle strength and gait speed

Sample size was small (8 older adults), and this is early-stage work, but the mechanistic argument is sound. If you’re supplementing NAC with longevity applications in mind, the evidence increasingly suggests that pairing it with glycine (which is also cheap and has its own evidence base for sleep quality) is the smarter strategy.

Safety and Contraindications

NAC has a good safety profile at standard doses:

Common side effects: Nausea, GI upset (more common at doses ≥ 1,200 mg). Taking with food reduces this significantly.

Rare side effects: Headache, rash. Anaphylaxis has been reported with IV NAC (more common than with oral forms) but is rare.

Drug interactions to consider: - Nitroglycerin / isosorbide dinitrate: NAC enhances vasodilatory effects — can cause severe hypotension and headache. Avoid combination. - Activated charcoal: May bind NAC if taken simultaneously (relevant only in overdose contexts). - Chemotherapy agents: Mixed data — some studies suggest NAC may reduce efficacy of certain platinum-based chemotherapy agents. Discuss with oncologist.

Specific populations: - Pregnancy: Insufficient data. The FDA drug form is used in pregnancy emergencies, but routine supplementation during pregnancy should be discussed with a physician. - Asthma: Inhaled NAC can cause bronchospasm. Oral forms are generally well-tolerated.

How This Differs From What Examine.com and Healthline Cover

Most coverage of NAC focuses on the glutathione mechanism and lists applications. Here’s what most doesn’t address:

1. The FDA controversy and what it actually means — knowing the regulatory background helps you evaluate the compound more accurately than just reading benefit lists.
2. The dose-response relationship for COPD — 600 mg doesn’t work for exacerbation prevention; 1,200 mg does. Most articles don’t note this.
3. Why direct glutathione supplementation is inferior — this is a mechanistic point that affects purchasing decisions.
4. The GlyNAC angle — this is where the most interesting current research is, and most popular coverage hasn’t caught up.
5. Psychiatric timelines — the benefit emergence at 8–20 weeks is clinically important and rarely emphasized.

What to Buy

NAC is inexpensive. Standard capsule/tablet products at 600 mg are widely available. For higher-dose applications, look for products with 600–1,000 mg per capsule to reduce pill burden.

Check for third-party testing (USP, NSF, or Informed Sport certification) if you’re using it for athletic applications where contamination matters.

Given the regulatory uncertainty in the US, availability may fluctuate. Products sold for “liver support” or “respiratory health” have generally remained on shelves through the FDA review period, but the situation is worth monitoring.

The Bottom Line

NAC is one of the better-studied compounds in the supplement category with clear applications in liver health, respiratory support, and specific psychiatric contexts as an adjunct. The regulatory controversy is real but has not been resolved in a way that restricts access.

The most clinically robust evidence is in COPD exacerbation prevention (at 1,200 mg/day) and acute liver protection. The psychiatric applications have the most interesting emerging evidence but require longer trials than most people expect.

For general health applications, 600 mg/day is a reasonable starting point with a low side effect burden. If you’re interested in the longevity angle, the GlyNAC combination is where the more compelling recent data points.

Related: Glutathione and Antioxidant Defense | Glycine: The Underrated Sleep Amino Acid | How to Read a Supplement Study Without Getting Fooled